Brief: Atea Pharmaceuticals To Advance Global Phase 3 Registrational Study Of Bemnifosbuvir In High-Risk Non-Hospitalized Patients With Covid-19
13/09/2022 12:03
Sept 13 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS TO ADVANCE GLOBAL PHASE 3
REGISTRATIONAL
STUDY OF BEMNIFOSBUVIR IN HIGH-RISK NON-HOSPITALIZED PATIENTS
WITH COVID-19
* ATEA PHARMACEUTICALS INC - TRIAL EXPECTED TO INITIATE IN
Q4 2022
Source text for Eikon: ID:nGNX7krPkx
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM